| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Total revenue | 116,743 | |||
| Cost of services | 32,216 | |||
| Gross profit | 84,527 | |||
| Research and development | 19,829 | |||
| Selling and marketing | 23,510 | |||
| General and administrative | 44,439 | |||
| Loss (income) from operations | -3,251 | |||
| Change in fair value of financial liabilities | -3,401 | |||
| Interest expense, net | -562 | |||
| Other (expense) income, net | -174 | |||
| Total non-operating expense, net | -4,137 | |||
| Loss before income taxes | -7,388 | |||
| Income tax (expense) benefit | 247 | |||
| Net loss | -7,635 | |||
| Unrealized gain related to available for sale securities, net | 190 | |||
| Comprehensive loss | -7,445 | |||
| Basic loss per share, class a common stock (in dollars per share) | -0.27 | |||
| Diluted loss per share, class a common stock (in dollars per share) | -0.27 | |||
| Weighted-average shares outstanding of class a common stock - basic (in shares) | 28,797,730 | |||
| Weighted-average shares outstanding of class a common stock - diluted (in shares) | 28,797,730 | |||
GeneDx Holdings Corp. (WGSWW)
GeneDx Holdings Corp. (WGSWW)